Modulation of growth factor action: implications for the treatment of cardiovascular diseases.

A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J (1999) 1.89

Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS One (2007) 1.32

Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol (2009) 1.05

Coronary vessel development and insight towards neovascular therapy. Int J Exp Pathol (2009) 1.00

Inhibition of vascular smooth muscle cell proliferation by Gentiana lutea root extracts. PLoS One (2013) 0.84

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs (2011) 0.84

HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop (2008) 0.84

The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the suppression of oxidative stress and damage. PLoS One (2013) 0.81

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl (2013) 0.81

Protective effects of non-mitogenic human acidic fibroblast growth factor on hydrogen peroxide-induced damage to cardiomyocytes in vitro. World J Gastroenterol (2005) 0.79

Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases J (2009) 0.75